Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy

A Sainio, H Järveläinen - Molecular and cellular therapies, 2014 - Springer
Tumour cells create their own microenvironment where they closely interact with a variety of
soluble and non-soluble molecules, different cells and numerous other components within …

Potent antitumor effect of tumor microenvironment‐targeted oncolytic adenovirus against desmoplastic pancreatic cancer

Y Li, JW Hong, JE Oh, AR Yoon… - International journal of …, 2018 - Wiley Online Library
Pancreatic cancer is a leading cause of cancer‐related death. Desmoplastic pancreatic
tumors exhibit excessive extracellular matrix (ECM) and are thus highly resistant to …

[HTML][HTML] Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I …

SP Lau, L Klaase, M Vink, J Dumas, K Bezemer… - European Journal of …, 2022 - Elsevier
Background Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …

Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma

LC Cutmore, NF Brown, D Raj, S Chauduri, P Wang… - Pancreatology, 2020 - Elsevier
Background Death from pancreatic ductal adenocarcinoma (PDAC) is rising across the
world and PDAC is predicted to be the second most common cause of cancer death in the …

Hepatocyte growth factor from a clinical perspective: A pancreatic cancer challenge

W Rizwani, AE Allen, JG Trevino - Cancers, 2015 - mdpi.com
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States
and incidence rates are rising. Both detection and treatment options for pancreatic cancer …

[HTML][HTML] Pancreatic ductal adenocarcinoma: characteristics of tumor microenvironment and barriers to treatment

S Kane, A Engelhart, J Guadagno, A Jones… - Journal of the …, 2020 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma remains a highly aggressive disease, with a 5-year
relative survival rate of 10%. Numerous barriers to treatment exist, such as dense …

pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and …

D Dutta, P Ray, A De, A Ghosh, RS Hazra, P Ghosh… - Plos one, 2024 - journals.plos.org
Therapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the
deadliest types of aggressive malignancies, are limited and disappointing. Therefore …

DNA–SWCNT biosensors allow real-time monitoring of therapeutic responses in pancreatic ductal adenocarcinoma

S Bhattacharya, X Gong, E Wang, SK Dutta… - Cancer research, 2019 - AACR
Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic cancer with limited
treatment options. There is an urgent need for tools that monitor therapeutic responses in …

Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

OT Olaoba, M Yang, TI Adelusi, T Maidens, ET Kimchi… - Cancers, 2024 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly
desmoplastic and extreme immunosuppressive tumor microenvironment (TME), which …

[HTML][HTML] Sonodynamic therapy combined with novel anti-cancer agents, sanguinarine and ginger root extract: Synergistic increase in toxicity in the presence of PANC …

M Prescott, J Mitchell, S Totti, J Lee, E Velliou… - Ultrasonics …, 2018 - Elsevier
The presence of ultrasound-induced cavitation in sonodynamic therapy (SDT) treatments
has previously enhanced the activity and delivery of certain sonosensitisers in biological …